Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics
✍ Scribed by David T. Kiang; B. J. Kennedy; Jerry Younger; Michael C. Perry; Albert Schilling; Ann H. Korzun; Barbara S. Nowak; William Wood
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 476 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background. Chemotherapy is most effective when applied during the biologically active stage of tumor cells. According to the authors' previous tumor marker kinetic study, methotrexate plus 5-fluorouracil (MF) was found to yield either a cytolytic effect in an MF-sensitive tumor cell population or a cytostatic effect in an MF-resistant population. In the latter, the suppressive effect was transient and the biologic activity resumed in one week after MF administration.
Methods. Based on this marker kinetic study, an alternating chemotherapy program was designed to study its antitumor and side effects. Methotrexate (M) (200 mg/ m') and 5-fluorouracil (F) (500 mg/m") were administered intravenously on day 1 followed 24 hours later by leucovorin (L) (10 mg/m2 orally every 6 hours for 6 doses). Cyclophosphamide (C) 300 (mg/m'), doxorubicin (A) (50 mg/ m'), and vincristine (V) (1 mg/m") were given on day 8. The MFL/CAV was given every 4 weeks.
Results. Forty-nine patients with metastatic breast cancer were enrolled; 41 were eligible. There were 5 com-